APTAR PHARMA CO-ORGANIZES THE FIFTH SYMPOSIUM ON INNOVATIVE DRUG DELIVERY SOLUTIONS IN SUZHOU, CHINA

Louveciennes, France - March 24th, 2014 - Global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, Aptar Pharma, co-organizes the fifth symposium on Innovative Drug Delivery Solutions. This symposium will be held in Suzhou, China, from March 24 to March 26, 2014.

A broader spectrum of innovative drug delivery topics

Over 200 participants from Asia, Europe and the USA will attend the three day scientific symposium, held every two years in China. The symposium will deal with a wide range of innovative technologies, including inhaled and nasal, preservative free, and injectable delivery solutions.

The 2014 symposium has a broader scope than in previous years. This change echoes expectations from the audience and provides Aptar Pharma with the opportunity to present several topics on injectables as well as on preservative-free systems, such as the latest technologies used for eye drops and multi-dose nasal sprays.

A panel of 14 highly distinguished regulatory, scientific and technical experts will explore and discuss the challenges facing these drug delivery solutions. Symposium lectures and discussion panels will include:

- Dr. Guiliang Chen, SIFDC (China): “Nebulizer Solution Development and Quality Control”
- Dr. Thommandru Vijaya Kumar, Vice-President Pharma Research, Lupin (India): “Respiratory Products Regulatory Pathway and its Market Potential in India”
- Dr. Degenhard Marx, Director Scientific Affairs Consumer Health Care Division, Aptar Pharma (Germany): “An Innovative Drug Delivery Solution: Preservative-Free Systems”
- Mr. Huimin Sun, CFDA (China): “Packaging Compatibility Study on Inhalation Drugs”
- Pr. Jiasheng Tu, China Pharmaceutical University (China): “Research on DPI Products (Design, Device and Excipients)”
- Dr. Gerralt Williams, Director Scientific Affairs Prescription Division, Aptar Pharma (France): “Inhalation Drugs: Current Developments & Global Trends”
- Mr. Yongjian Yang, SIFDC (China): “Key Parameters Affecting the Quality of Inhalation Drugs”
- Dr. Xian-Ming Zeng, Senior Vice President Inhalation R&D, Lupin (USA): “Experience with Generic Drug Development & Manufacture”
- Dr. Kai Zhang, Omni (China): “The Evaluation and Application of DPI Devices”
- Mr. Joel Cotten, Business Development Director, Aptar Stelmi (France): “Pre-filled Syringes and New Market Needs”
- Mr. Qiming Zhang, CFDA (China): “Chinese Pharmacopeia 2015: Requirements Change on Inhalation Drugs”
- Pr. Xin Zhou, Director of Respiration Department, Shanghai First People’s Hospital (China): “The Pathogenesis, Treatment and Medication in Asthma & C.O.P.D”
- Mr. Gang Wang, R&D Director, Shangdong Weigao (China): “The Application of Pre-filled Syringes in Biologics”
- Dr. Philippe Le Gall, Director Technical Support & Regulatory Affairs, Aptar Stelmi (France): “Lyophilization: Preservation of Moisture Sensitive Drugs”
Evolution of regulatory requirements for drug delivery devices

International, regional and local market regulatory standards that govern the drug delivery systems in discussion during this symposium are evolving rapidly.

Recent regulatory standards directly related to respiratory products or to demonstrating their equivalence include the European EMEA guideline for OIP (orally inhaled products, CPMP/EWP/4151/2009), and US guidances related to BA/BE for various aerosol forms:
- pMDI, salbutamol (FDA/UCM346985)
- DPI, fluticasone/salmeterol (FDA/UCM367643)
- Nasal spray, ketorolac (FDA/UCM347003)

In addition, the recent updates to the Chinese Pharmacopeia (ChP2010) reflect significantly increased requirements for aerosol products.

Recent standards for injectables include the following:
- The FDA rule for combination products, such as pen and auto-injectors, that will require manufacturers to comply with both the good manufacturing practice regulations for pharmaceuticals and the quality system regulation for medical devices.
- FDA draft guidance which identifies additional, technical information that should be submitted by sponsors who seek to rely on conformity to ISO 11040-4 for a glass syringe product.

Specialized companies, such as Aptar Pharma, that partner with pharmaceutical companies to develop these various drug delivery forms have also expanded their levels of scientific understanding and expertise, in order to meet these increasing regulatory and quality standards and successfully support these continuously evolving market needs worldwide.

Aptar Pharma established in China since 1996

Aptar Pharma is actively supporting the pharmaceutical industry’s business opportunities in emerging markets. We are well established in China, where our Suzhou site near Shanghai has been manufacturing several Aptar Pharma product lines since 1996. We are committed to providing excellence in the quality of our products manufactured at Suzhou, as at all of our sites worldwide.

Aptar Pharma Suzhou employs some 270 people and is certified by the CFDA, the Chinese pharmaceutical regulatory body, to manufacture metering valves and spray pumps. The site serves the majority of the local Chinese pharmaceutical companies, whether they are producing drug products for the domestic Chinese market or for other Asian regions.

“Aptar Pharma has been market leader in China for more than a decade, and we are very pleased to co-organize this fifth symposium and welcome key opinion leaders from China, India and other countries around the world. This symposium is part of our long-standing effort to provide a high quality platform for expert presentations and discussions about a broad range of drug delivery applications”, said Jiang Yang, General Manager & Vice President, Aptar Pharma China & North east Asia.

About Aptar Pharma

Aptar Pharma is part of the AptarGroup, Inc. family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by decades of proven expertise.

AptarGroup, Inc. (NYSE: ATR) is headquartered in Crystal Lake, Illinois, United States, with manufacturing facilities in North America, Europe, Asia and South America.

For more information, visit www.aptar.com/pharma

Press Contacts

Elisa Eschylie, Events and Press relations manager
Tel. : +33 (0)1 39 17 20 41 - E-mail : elisa.eschylie@aptar.com

Marion Baschet Vernet, Attachée de presse
Tel. : +33 (0)6 22 17 08 96 - E-mail : mbvernet@gmail.com

Delivering solutions, shaping the future.